Johnson & Johnson (NYSE:JNJ) Trading Up 0.7% - What's Next?

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s share price rose 0.7% on Friday . The company traded as high as $164.15 and last traded at $164.31. Approximately 1,319,497 shares changed hands during trading, a decline of 81% from the average daily volume of 7,057,959 shares. The stock had previously closed at $163.13.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. Leerink Partners lowered their price target on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Raymond James cut their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $171.33.

Johnson & Johnson Stock Up 1.3 %

The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $399.76 billion, a price-to-earnings ratio of 24.95, a PEG ratio of 2.56 and a beta of 0.47. The firm's fifty day moving average is $158.68 and its 200-day moving average is $156.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.29 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 2.99%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. IFS Advisors LLC increased its position in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after acquiring an additional 100 shares during the period. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson during the 4th quarter worth about $29,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $32,000. Finally, Conquis Financial LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth approximately $33,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.